Recombinant hepatitis B surface antigen and recombinant vaccine, recombinant DNA sequence and transformed Saccharomyces cerevisiae

A previous seroepidemiological study in the rural zone of Vargem Alta (ES) SouthEast of Brazil, showed a prevalence of up to 9% of hepatitis B surface antigen (HBsAg) in some areas. One hundred susceptible children aging 1 to 5 years old were selected and immunized with a recombinant DNA hepatitis B vaccine (Smith-Kline 20 mcg) using the 0-1-6 months vaccination schedule. Blood samples were collected at the time of the first vaccine dose (month 0) in order to confirm susceptible individuals and 1,3,6 and 8 months after the first dose , to evaluate the antibody response. Our results showed that two and five months after the second dose, 79% and 88% of children seroconverted respectively, reaching 97% after the third dose. The levels of anti-HBs were calculated in milli International Units/ml (mIU/ml) and demonstrated the markedly increase of protective levels of antibodies after the third dose. These data showed a good immunogenicity of the DNA recombinant hepatitis B vaccine when administered in children of endemic areas.

Download Full-text

Physicochemical properties of recombinant hepatitis B surface antigen expressed in mammalian cell (C127)

Archives of Pharmacal Research ◽

10.1007/bf02975368 ◽

1998 ◽

Vol 21 (5) ◽

pp. 521-526 ◽

Cited By ~ 4

Author(s):

Young Soo Lee ◽

Byong Kak Kim ◽

Eung-Chil Choi

Keyword(s):

Hepatitis B ◽

Physicochemical Properties ◽

Mammalian Cell ◽

Surface Antigen ◽

Hepatitis B Surface Antigen ◽

Recombinant Hepatitis

Download Full-text

Hepatitis B surface antigen polypeptide micelles from antigen expressed in Saccharomyces cerevisiae

Journal of Virological Methods ◽

10.1016/0166-0934(86)90004-2 ◽

1986 ◽

Vol 14 (1) ◽

pp. 25-35 ◽

Cited By ~ 4

Author(s):

C.R. Howard ◽

P.R. Young ◽

S. Lee ◽

J. Dixon ◽

A.J. Zuckerman ◽

...

Keyword(s):

Saccharomyces Cerevisiae ◽

Hepatitis B ◽

Surface Antigen ◽

Hepatitis B Surface Antigen

Download Full-text

Efficacy of Immunization with a Combination of Serum and Recombinant Hepatitis B Vaccines

Infection Control and Hospital Epidemiology ◽

10.1086/646783 ◽

1993 ◽

Vol 14 (8) ◽

pp. 476-478 ◽

Cited By ~ 1

Author(s):

Karlyn K. Pearl ◽

Ana A. Ortiz ◽

William Pearl

Keyword(s):

Hepatitis B ◽

Healthcare Workers ◽

Hepatitis B Surface Antigen ◽

The United States ◽

Recombinant Vaccine ◽

Vaccine Group ◽

Recombinant Hepatitis ◽

The Third ◽

Hepatitis B Vaccines ◽

One Year

AbstractObjective:To evaluate the efficacy of giving a third dose of recombinant hepatitis B vaccine to healthcare workers who already had received two doses of serum-derived vaccine, which is no longer available in the United States.Design:Volunteers who already had received two standard doses of serum-derived vaccine were given a third dose of either serum or recombinant vaccine in a double-blind fashion. Antibodies to hepatitis B surface antigen were measured at the time of the third immunization, three months later, and one year after the third immunization.Setting:U.S. Army Medical Center, El Paso, Texas.Patients:One hundred healthy healthcare workers.Results:Three months after receiving the third immunization, the serum vaccine group had significantly higher titers than the recombinant vaccine group (P= 0.018). One year after receiving the third immunization, those who received the combined regimen had a mean hepatitis B surface antibody titer less than half that of those who received three doses of serum-derived vaccine. However, both regimens resulted in titers that are considered to confer immunity.Conclusions:A regimen that combines serum and recombinant hepatitis B vaccines may not produce as high an antibody level as three doses of the same vaccine. Those who began immunization with serum vaccine and concluded with recombinant vaccine should be monitored for an accelerated drop in serum antibodies.

Download Full-text